

TIGER GLOBAL OBESITY TREATMENT TOP 2 PLUS INDEX TIGER ETF

April 30, 2024

Investment Objective

The investment trusts constructs an index of listed companies in developed countries that generate revenue or conduct R&D related to obesity treatments, with the top two holdings by market capitalization representing 25% each and the remaining eight holdings weighted by market capitalization. The trust does not hedge its foreign currency assets, so the net asset value per share will be linked to the KRW conversion rate of the underlying index.

Underlying Index

Indxx Global Obesity Treatment Top 2 Plus Index invests in publicly traded companies in developed countries that generate revenue or conduct R&D related to the obesity treatment theme.

Dividend Information(2Y)

record date	dividend yield	dividend per share (DPS)
2024.04.02	0.15	15

Basic Information


Inception Date	February 28, 2024
Underlying Assets	Overseas Equity
Net Assets	49,820mil. KRW
NAV per share	10,379.07KRW
Total Expense Ratio	(annual) 0.45 %
Distributions	Last business day of the month, End of fiscal year
Asset Manager	Mirae Asset Global Investments
Custodian	Citibank Korea Co.,Ltd.
Administration	Korea Fund Partners
AP/LP	Please refer to our website(www.tigeretf.com)

Performance

	1M	3M	6M	1Y	2Y	YTD	Since Inception	Volatility
TIGER GLOBAL OBESIT	0.23	-	-	-	-	-	4.04	5.52
Indxx Global Obesity Tr	0.22	-	-	-	-	-	2.42	5.31

* The performances are total returns.

* Volatility: annualized standard deviation based on daily performances of recent one year.



Top 10 Holdings

No	Name	Sector	Val Amt(KRW)	Weighting(%)
1	Eli Lilly & Co		125,924,965	24.27
2	Novo Nordisk A/S		124,444,589	23.98
3	Merck & Co Inc		62,003,949	11.95
4	AstraZeneca PLC		43,394,357	8.36
5	Roche Holding AG		37,841,062	7.29
6	Novartis AG		37,757,796	7.28
7	Amgen Inc		27,882,872	5.37
8	Pfizer Inc		27,238,484	5.25
9	Regeneron Pharmaceuticals Inc		18,377,769	3.54
10	Chugai Pharmaceutical Co Ltd		9,864,216	1.90

* The above is in accordance with GICS-sector.

This document has been prepared for presentation, illustration and discussion purpose only and is not legally binding. Whilst compiled from sources Mirae Asset Global Investments believes to be accurate, no representation, warranty, assurance or implication to the accuracy, completeness or adequacy from defect of any kind is made. The information presented is not intended to provide specific investment advice. Please carefully read through the offering documents and seek independent professional advice before you make any investment decision.